167 related articles for article (PubMed ID: 34584426)
1. Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.
Wang KX; Cui TY; Yang XD; Wang GQ; Jiang QS; Sun H; Jiang NY; Yong XM; Shi CB; Ding YB; Chen XF; Fang YY
Onco Targets Ther; 2021; 14():4859-4865. PubMed ID: 34584426
[TBL] [Abstract][Full Text] [Related]
2. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
[TBL] [Abstract][Full Text] [Related]
3. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
[TBL] [Abstract][Full Text] [Related]
5. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
7. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S; Chan SL; Gu S; Bai Y; Ren Z; Lin X; Chen Z; Jia W; Jin Y; Guo Y; Hu X; Meng Z; Liang J; Cheng Y; Xiong J; Ren H; Yang F; Li W; Chen Y; Zeng Y; Sultanbaev A; Pazgan-Simon M; Pisetska M; Melisi D; Ponomarenko D; Osypchuk Y; Sinielnikov I; Yang TS; Liang X; Chen C; Wang L; Cheng AL; Kaseb A; Vogel A;
Lancet; 2023 Sep; 402(10408):1133-1146. PubMed ID: 37499670
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Wang D; Yang X; Long J; Lin J; Mao J; Xie F; Wang Y; Wang Y; Xun Z; Bai Y; Yang X; Guan M; Pan J; Seery S; Sang X; Zhao H
Front Oncol; 2021; 11():646979. PubMed ID: 33912461
[TBL] [Abstract][Full Text] [Related]
10. Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study.
Qu Y; Munire A; Zhou N; Saifuding K; Bulibu J; Wang W; Tang X; Li N; Li J; Wang P; Tang Y
J Gastrointest Oncol; 2024 Feb; 15(1):1-11. PubMed ID: 38482217
[TBL] [Abstract][Full Text] [Related]
11. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.
Li S; Bao J; Li X; Yang Q; Xu J; Chen S; Feng G; Gao C; Feng L; Lu B; Miao M; Ni X; Wang G; Yang L; Zhu L
EClinicalMedicine; 2023 Dec; 66():102314. PubMed ID: 38024480
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
15. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study.
Wu K; Li Y; Li Z; Zhou Z; Ge X; Li Y; Han X; Chen P; Ren K
Front Oncol; 2023; 13():1143578. PubMed ID: 37746269
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
Mao L; Lian B; Li C; Bai X; Zhou L; Cui C; Chi Z; Sheng X; Wang X; Tang B; Yan X; Li S; Kong Y; Dai J; Wei X; Li J; Duan R; Xu H; Wu X; Yang Y; Cheng F; Zhang C; Xia F; Pang Z; Guo J; Si L
JAMA Oncol; 2023 Aug; 9(8):1099-1107. PubMed ID: 37261804
[TBL] [Abstract][Full Text] [Related]
19. Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.
Deng YY; Jiang DY; Zhu PF; Lu H; Liu Q; Zhang X; Pan SY; Chen ZL; Yang L
World J Surg Oncol; 2023 Apr; 21(1):129. PubMed ID: 37041581
[TBL] [Abstract][Full Text] [Related]
20. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
Xing P; Wang M; Zhao J; Zhong W; Chi Y; Xu Z; Li J
Thorac Cancer; 2021 Oct; 12(20):2825-2828. PubMed ID: 34409776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]